09:47 AM EST - HLS Therapeutics Inc. : Announced its financial results for the three months ended June 30, 2026. All amounts are in thousands of United States dollars unless otherwise stated. Q2 2026 revenue was $14.7 million, Adjusted EBITDA was $4.7 million and cash from operations was $2.9 million, compared to $14.2 million, $5.2 million and $4.6 million, respectively. HLS Therapeutics Inc.
shares T.HLS are trading up $0.07 at $3.90.
